Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

SNSS 2.22 0.00 (0.00%)
price chart
BTIG Initiates Coverage On Sunesis Pharmaceuticals, Believes Company 'Will ...
BTIG initiated coverage on Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) Monday with a Buy rating and $5.50 price target.
Sunesis Pharmaceuticals Coverage Initiated by Analysts at BTIG Research (SNSS)  WKRB News
Related articles »  
Is This the Sunesis Resurrection?
In early October, Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) announced that its Phase 3 clinical trial of vosaroxin and cytarabine failed to meet the primary endpoint of the study, which ultimately had catastrophic results for the stock price ...
Sunesis Pharmaceuticals (SNSS) Stock Surges on Upcoming Announcement of ...
Related articles »  
Sunesis Pharmaceuticals Inc Stock Downgraded (SNSS)
Despite a decrease in cash flow of 20.20%, SUNESIS PHARMACEUTICALS INC is in line with the industry average cash flow growth rate of -24.34%.
Related articles »  
Sunesis Pharmaceuticals Inc. (SNSS) Jumps 7.17% on February 18
Sunesis Pharmaceuticals Inc. ($SNSS) was among the biggest gainers on the Russell 2000 for Wednesday February 18 as the stock popped 7.17% to $2.39, representing a gain of $0.16 per share.
Sunesis Pharmaceuticals, Inc. (SNSS) Jumps: Stock Rises 9%
Sunesis Pharmaceuticals, Inc. (SNSS - Snapshot Report) was a big mover last session, as the company saw its shares rise more than 9% on the day.
Related articles »  
Sunesis Pharmaceuticals, Inc. Short Interest Drops by -7.4%
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has shown a drop of 7.4% or 383,098 shares in the short positions. The bets have increased to 4,824,440 shares on January 30,2015 from 5,207,538 shares on January 15,2015.
Sunesis Pharmaceuticals, Inc. Registers High Short Percent of Float
Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) are trading at $2.42. The price is 71.4% off the 52-week high and 58.7% off the 52-week low.
Sunesis Pharmaceuticals, Inc. Registers High Short Interest
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS): Each share of Sunesis Pharmaceuticals Inc is priced at $2.23, which is 73.6% below the 52-week high.
UPDATE: UBS Starts Sunesis Pharmaceuticals Inc. (SNSS) at Buy
UBS initiated coverage on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) with a Buy rating and a price target of $14.00. Analyst Andrew Peters said, "Key points from our analysis: [1] SNSS provides an exceptionally high risk/reward ahead of the ph3 VALOR ...
Related articles »  
Zacks Rating Update on Sunesis Pharmaceuticals, Inc.
As much as 7 analysts have advised buy on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) with an average broker rating of 2.43.